Methods and tools for the diagnosis and prognosis of urogenital cancers
AssigneeCancer Genetics, Inc.
InventorsJane C. Houldsworth, Raju S.K. Chaganti
Life of this patent
Estimating the term…
Loading patent…
AssigneeCancer Genetics, Inc.
InventorsJane C. Houldsworth, Raju S.K. Chaganti
Estimating the term…
The present invention provides a microarray useful as a tool in the diagnosis and/or prognosis of certain types of cancers, particularly urogenital cancers. The microarray can include a plurality of genomic regions represented thereon, the genomic regions corresponding to regions wherein alterations, such as copy number aberrations, at such locations correlate to specific, identifiable cancers, particularly prostate, renal, or bladder tumors. The invention further provides methods of diagnosing certain types of cancers, particularly urogenital cancers, more particularly renal cortical cancers. The methods can comprise analyzing genetic material from a human individual to determine the presence or presence of certain aberrations and using a decision tree to classify the subtype of renal cortical neoplasm present in the sample.
A method of diagnosing renal cortical neoplasms, the method comprising:
A kit comprising a microarray suitable for the detection of genomic aberrations and the decision tree set forth in FIG. 3, wherein the aberrations comprise the loss of VHL gene, the loss of chr2, the gain of 17q, the gain of chr7, the gain of chr12, the gain of 16p, the gain of 20q, the gain of 5qter, the gain of chr3, the loss of chr6, the loss of chr10, the loss of chr17, the loss of 8p, the partial or entire loss of chr1, and the loss of 3p21.2-21.31.
A microarray for determining the type or predicting the disease progression of prostate, renal, or bladder tumors present in a sample, said microarray comprising a substrate with a plurality of nucleic acid molecules corresponding to distinct genomic regions arrayed thereon, wherein an alteration in at least one of said distinct genomic regions is correlated to the diagnosis or prognosis of one or more types of tumors mentioned above, and wherein said at least one distinct genomic region is selected from the group consisting of the distinct genomic regions set forth in at least one of Tables 3-8.
Dependencies are inferred from the claim text.